• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS )

    15.92 -0.14 (-0.87%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 124,552
    Open 16.06
    Bid (Size) 15.31 (1)
    Ask (Size) 25.50 (2)
    Prev. Close 16.06
    Today's Range 15.87 - 16.15
    52wk Range 5.633 - 26.35
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire

    Performance

    YTD
    +33.22%
    +33.22%
    1 Month
    -3.69%
    -3.69%
    3 Month
    -18.90%
    -18.90%
    6 Month
    -29.12%
    -29.12%
    1 Year
    +69.18%
    +69.18%

    More News

    Read More
    NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
    Via Benzinga
    NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results
    Via Benzinga
    Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
    Via Investor's Business Daily
    NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    Via Investor's Business Daily
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
    From NewAmsterdam Pharma N.V
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.